Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Date:2/29/2008

rom baseline to Week 4. Safety evaluations included incidence of adverse reactions, discontinuation due to adverse reactions, laboratory measures and body weight.

For the primary endpoint, both doses of ABILIFY demonstrated statistically significant improvement in symptoms when compared to placebo (p-value less than 0.0001) as measured by the mean change from baseline to endpoint (Week 4) on the Y-MRS Total Score. The efficacy of ABILIFY for the maintenance treatment of Bipolar I Disorder in the pediatric population has not been evaluated.

Approximately 80% of patients completed the four-week study (ABILIFY 10 mg: 86%; ABILIFY 30 mg: 78%; placebo: 77%). There was a low rate of discontinuation due to adverse reactions at Week 4 (ABILIFY: 7%; placebo: 2%).

During the study, the most commonly observed adverse reactions (greater than or equal to 5% in combined ABILIFY groups and at least twice the rate of placebo) associated with ABILIFY were: somnolence (ABILIFY: 23%; placebo: 3%), extrapyramidal disorder (ABILIFY: 20%; placebo: 3%), fatigue (ABILIFY: 11%; placebo: 4%), nausea (ABILIFY: 11%; placebo: 4%), akathisia (ABILIFY: 10%; placebo: 2%), blurred vision (ABILIFY: 8%; placebo: 0%), salivary hypersecretion (ABILIFY: 6%; placebo: 0%) and dizziness (ABILIFY: 5%; placebo: 1%). Four common adverse reactions had a possible dose-response relationship at Week 4: extrapyramidal disorder (ABILIFY 10 mg: 12.2%; ABILIFY 30 mg: 27.3%; placebo: 3.1%), somnolence (ABILIFY 10 mg: 19.4%; ABILIFY 30 mg: 26.3%; placebo: 3.1%), akathisia (ABILIFY 10 mg: 8.2%; ABILIFY 30 mg: 11.1%; placebo: 2.1%) and salivary hypersecretion (ABILIFY 10 mg: 3.1%; ABILIFY 30 mg: 8.1%; placebo: 0%). Children and adolescents might be more sensitive than adults in developing antipsychotic-related adverse events.(1)

In the study, weight gain greater than or equal to 7% change from baseline was seen in 3.2%, 9.4% and 3.3% for the ABILIFY 10 mg, ABILIFY 30 mg and placebo groups, res
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
5. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
6. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
7. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
10. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. , (OTCQB: DMPI), developer of ... presenting company at the 16th Annual Rodman & Renshaw ... & Co., LLC. The presentation will take place Tuesday, September ... Salon (4th floor) at the New York Palace Hotel ...
(Date:8/27/2014)... FAIRFAX, Va. , Aug. 27, 2014 ... in the legs due to buildup of fatty plaque ... expected in the aging patient population and in incidences ... Radiology offers its Lower Extremity Arterial RevascularizatioN ... Ariz. Endovascular specialists and interested residents and ...
(Date:8/27/2014)... Research and Markets  has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
Breaking Medicine Technology:DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3Global Pulse Oximeter Industry Report 2014 2
... 6, 2011 Agendia, an innovative molecular diagnostics ... paraffin embedded tissue technology applied to their Symphony™ ... in a paraffin embedded tissue format offers their ... development and validation found in Agendia,s breast cancer ...
... 6, 2011  TRACE released the 2011 BRIBEline United ... demands for bribes reported in specific countries.  Previous reports ... Ukraine, Russia, India and China. "The ... contribution to the prevention of bribery," said TRACE Founder ...
Cached Medicine Technology:Agendia Introduces the SYMPHONY™ Breast Cancer Profile With Paraffin Embedded Tissue 2TRACE Releases Report on Bribe Demands in the United States 2TRACE Releases Report on Bribe Demands in the United States 3
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Latinos ... 5th, 6th and 7th at the Florida State Fair ... celebrates all Latino art and cultures from around the ... their platinum sponsor Go Smart Mobile and Univision Mobile, ... Festival is expecting an estimate of 4,000 people from ...
(Date:8/27/2014)... 27, 2014 New Jersey’s own Morgan ... Ridgewood County Club during The Barclays – and thanks ... of the tournament’s four rounds, stepped his way into ... Cross Blue Shield of New Jersey (Horizon BCBNSNJ) Walking ... Wyckoff native playing before family and friends at the ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Seventy-three members ... Pharmacy (SoP) celebrated the beginning of their careers as ... Saturday, August 23. Students entering a four-year PharmD program ... care ?to welcome them into the profession as colleagues ... ceremony held at the Garrison Theater in Claremont, Calif., ...
(Date:8/27/2014)... therapy has spawned a prevalent but preventable side effect: ... according to a study by a Yale School of ... published in the Aug. 27 online issue of the ... to severe hot flashes also called vasomotor symptoms ... with VMS experience more than feeling hot; other frequently ...
(Date:8/27/2014)... Dennis Thompson HealthDay Reporter ... who has been mugged in a dark alley will likely ... a fear of being attacked. But neuroscientists working with ... memories are linked with positive and negative emotions. And in ... attached to a memory. In essence, they made once-reluctant ...
Breaking Medicine News(10 mins):Health News:Marc Anthony to Perform at "Nieves Productions" Latinos in Action Festival 2Health News:Morgan Hoffmann, PGA TOUR Pro & Wyckoff Native, golfs and walks his way to top 10 finish at The Barclays while raising additional $7,500 for charity 2Health News:Founding Class of the KGI School of Pharmacy Formally Welcomed into the Profession at a Traditional White Coat Ceremony 2Health News:The high cost of hot flashes: Millions in lost wages preventable 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3
... FRIDAY, March 4 (HealthDay News) -- A diet rich in foods ... stroke by 21 percent and may also lower your risk of ... include bananas and other fruits and vegetables, as well as fish, ... sweet potato and tomato paste top the list, according to the ...
... designed to assist weight loss by limiting the amount of ... It has been used for several years to treat obesity ... Clinical Obesity reveals that bariatric surgery can result in ... Aikenhead of the International Association for the Study of Obesity ...
... News)-- Men need more support before and after their child ... they were happy to attend childbirth classes for their partner,s ... and did not have a ready outlet for their own ... for a University of Gothenburg thesis by midwife Asa Premberg ...
... ALS or more popularly, Lou Gehrig,s disease, is a ... brain and spinal cord neurons, resulting in the gradual ... In a new paper, published in the ... Nature Neuroscience , a team of scientists at the ...
... , FRIDAY, March 4 (HealthDay News) -- Poor ... of people worldwide at risk for early death, a ... treatment and management in Colombia, England, Iran, Mexico, Scotland, ... of U.S. adult diabetics -- more than 16 million ...
... Professor of Molecular & Cell Biology at Boston University ... of Microbiology at Boston University School of Medicine discovered ... of gene expression. The study describing this work titled, ... Premature Transcription Termination," appears in the March 4 issue ...
Cached Medicine News:Health News:Potassium-Rich Foods May Cut Stroke, Heart Disease Risk 2Health News:Potassium-Rich Foods May Cut Stroke, Heart Disease Risk 3Health News:Study Finds Men Need More Support Before, After Child Birth 2Health News:Loss of key protein boosts neuron loss in ALS 2Health News:Diabetes Often Not Diagnosed or Treated Properly 2Health News:Novel mechanism for control of gene expression revealed 2
Open wire style 16 mm blade with a wing tip twist giving the surgeon better on-axis accessibility....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: